Xemilofiban

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 341403

CAS#: 149820-74-6

Description: Xemilofiban is a biochemicla.


Chemical Structure

img
Xemilofiban
CAS# 149820-74-6

Theoretical Analysis

MedKoo Cat#: 341403
Name: Xemilofiban
CAS#: 149820-74-6
Chemical Formula: C18H22N4O4
Exact Mass: 358.1641
Molecular Weight: 358.398
Elemental Analysis: C, 60.32; H, 6.19; N, 15.63; O, 17.86

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: Xemilofiban; SC 54684A; SC-54684A; SC54684A.

IUPAC/Chemical Name: 4-Pentynoic acid, 3-((4-((4-(aminoiminomethyl)phenyl)amino)-1,4-dioxobutyl)amino)-, ethyl ester, (S)-

InChi Key: ZHCINJQZDFCSEL-CYBMUJFWSA-N

InChi Code: InChI=1S/C18H22N4O4/c1-3-13(11-17(25)26-4-2)21-15(23)9-10-16(24)22-14-7-5-12(6-8-14)18(19)20/h1,5-8,13H,4,9-11H2,2H3,(H3,19,20)(H,21,23)(H,22,24)/t13-/m1/s1

SMILES Code: C#C[C@@H](NC(CCC(NC1=CC=C(C(N)=N)C=C1)=O)=O)CC(OCC)=O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 358.398 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Brugts JJ, Mercado N, Hu S, Guarneri M, Price M, Schatz R, Teirstein P, Wijns W, Serruys PW, O'Neill WW, Boersma E. Relation of periprocedural bleeding complications and long-term outcome in patients undergoing percutaneous coronary revascularization (from the Evaluation of Oral Xemilofiban in Controlling Thrombotic Events [EXCITE] Trial). Am J Cardiol. 2009 Apr 1;103(7):917-22. doi: 10.1016/j.amjcard.2008.12.017. Epub 2009 Feb 7. PubMed PMID: 19327416.

2: Mercado N, Brugts JJ, Ix JH, Shlipak MG, Dixon SR, Gersh BJ, Lemos PA, Guarneri M, Teirstein PS, Wijns W, Serruys PW, Boersma E, O'Neill WW. Usefulness of proteinuria as a prognostic marker of mortality and cardiovascular events among patients undergoing percutaneous coronary intervention (data from the Evaluation of Oral Xemilofiban in Controlling Thrombotic Events [EXCITE] trial). Am J Cardiol. 2008 Nov 1;102(9):1151-5. doi: 10.1016/j.amjcard.2008.06.035. Epub 2008 Aug 9. PubMed PMID: 18940282.

3: Sheppard LP. Xemilofiban Searle and Co. IDrugs. 1998 Jun;1(2):257-63. PubMed PMID: 18465540.

4: Gowda RM, Khan IA, Vasavada BC, Sacchi TJ. Therapeutics of platelet glycoprotein IIb/IIIa receptor antagonism. Am J Ther. 2004 Jul-Aug;11(4):302-7. Review. PubMed PMID: 15266223.

5: Lapchak PA, Araujo DM. Therapeutic potential of platelet glycoprotein IIb/IIIa receptor antagonists in the management of ischemic stroke. Am J Cardiovasc Drugs. 2003;3(2):87-94. Review. PubMed PMID: 14727935.

6: Tendera M, Wojakowski W. Role of antiplatelet drugs in the prevention of cardiovascular events. Thromb Res. 2003 Jun 15;110(5-6):355-9. Review. PubMed PMID: 14592562.

7: Xemilofiban: SC 54684A, xemlofiban. Drugs R D. 2003;4(6):389-94. Review. PubMed PMID: 14584975.

8: Doggrell SA. Clinical trials with glycoprotein IIb/IIIa antagonists - No benefit without bleeding? Drugs Today (Barc). 2001 Aug;37(8):509-531. PubMed PMID: 12743636.

9: Brassard JA, Curtis BR, Cooper RA, Ferguson J, Komocsar W, Ehardt M, Kupfer S, Maurath C, Swabb E, Cannon CP, Aster RH. Acute thrombocytopenia in patients treated with the oral glycoprotein IIb/IIIa inhibitors xemilofiban and orbofiban: evidence for an immune etiology. Thromb Haemost. 2002 Dec;88(6):892-7. PubMed PMID: 12529735.

10: Abrams CS, Cines DB. Platelet glycoprotein IIb/IIIa inhibitors and thrombocytopenia: possible link between platelet activation, autoimmunity and thrombosis. Thromb Haemost. 2002 Dec;88(6):888-9. Review. PubMed PMID: 12529733.

11: Mackin L, Sartnurak S, Thomas I, Moore S. The impact of low levels of amorphous material (<5%) on the blending characteristics of a direct compression formulation. Int J Pharm. 2002 Jan 14;231(2):213-26. PubMed PMID: 11755273.

12: Ashraf-Khorassani M, Taylor LT, Williams DG, Roston DA, Catalano TT. Demonstrative validation study employing a packed column pressurized fluid chromatography method that provides assay, achiral impurities, chiral impurity, and IR identity testing for a drug substance. J Pharm Biomed Anal. 2001 Dec;26(5-6):725-38. PubMed PMID: 11600285.

13: Frelinger AL 3rd, Furman MI, Krueger LA, Barnard MR, Michelson AD. Dissociation of glycoprotein IIb/IIIa antagonists from platelets does not result in fibrinogen binding or platelet aggregation. Circulation. 2001 Sep 18;104(12):1374-9. PubMed PMID: 11560852.

14: Anders R, Kleiman J, Nicholson N, Wazowicz B, Burns D. Xemilofiban/orbofiban: insight into drug development. Cardiovasc Drug Rev. 2001 Summer;19(2):116-32. Review. PubMed PMID: 11484066.

15: Nair GV, Davis CJ, McKenzie ME, Lowry DR, Serebruany VL. Aspirin in patients with coronary artery disease: is it simply irresistible? J Thromb Thrombolysis. 2001 Apr;11(2):117-26. Review. PubMed PMID: 11406726.

16: Easton JD. Future perspectives for optimizing oral antiplatelet therapy. Cerebrovasc Dis. 2001;11 Suppl 2:23-8. Review. PubMed PMID: 11316919.

17: Nicholson NS, Abood NA, Panzer-Knodle SG, Frederick LG, Page JD, Salyers AK, Suleymanov OD, Szalony JA, Taite BB, Anders RJ. Orbofiban: an orally active GPIIb/IIIa platelet receptor antagonist. Med Res Rev. 2001 May;21(3):211-26. PubMed PMID: 11301411.

18: Chew DP, Bhatt DL, Sapp S, Topol EJ. Increased mortality with oral platelet glycoprotein IIb/IIIa antagonists: a meta-analysis of phase III multicenter randomized trials. Circulation. 2001 Jan 16;103(2):201-6. PubMed PMID: 11208677.

19: Chew DP, Bhatt DL. Oral glycoprotein IIb/IIIa antagonists in coronary artery disease. Curr Cardiol Rep. 2001 Jan;3(1):63-71. Review. PubMed PMID: 11139801.

20: Cannon CP. Learning from the recently completed oral glycoprotein IIb/IIIa receptor antagonist trials. Clin Cardiol. 2000 Nov;23 Suppl 6:VI-14-7. PubMed PMID: 11129681.